Biotech Stock Arcutis Climbs into Buy Zone as FDA Mulls Expanded Use for Key Skin Treatment
Arcutis Biotherapeutics (ARQT) is currently in a buy zone and looks to stretch a winning streak, with the IBD 50 stocks To Watch pick for Thursday, and skin-disorders treatment specialist, appearing set to broaden its product reach and bolster sales. The biotech stock on T